Silver Book Fact

A calculated approximate benefit-to-cost ratio for antihypertensive therapy is 10:1 for men and 6:1 for women.

Cutler D, Long G, Berndt E, Royer J, et al. The Value Of Antihypertensive Drugs: A perspective on medical innovation. Health Affairs. 2007; 26(1): 97-110

Reference

Title
The Value Of Antihypertensive Drugs: A perspective on medical innovation
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Cutler D, Long G, Berndt E, Royer J, et al.
Volume & Issue
Volume 26, Issue 1
Pages
97-110

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • The rate of hospitalization from heart failure before and after transcatheter mitral valve repair (TMVR) decreases 73% (per patient year) in patients at prohibitive surgical risk.
     
  • Cardiovascular disease death rates
    Cardiovascular disease accounts for nearly 801,000 deaths in the US, or about 1 of every 3 deaths in the US.  
  • Cardiovascular disease mortality has declined by over 50% since 1950, contributing more than any other factor to the increase of life expectancy during the past few decades.  
  • Development of a neuroprotective drug could potentially reduce disability from stroke by 50%.  
  • Antihypertensive treatment has generated a benefit-to-cost ratio of at least 6:1 (6:1 in women and 10:1 in men).